Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Alzheimer's disease, Parkinson's disease, and Huntington's disease are common neurodegenerative diseases. Tau is a microtubule-associated protein, and aggregated tau resulting from hyperphosphorylation is a pathological feature of a group of neurodegenerative diseases known as tauopathies. The 18F-T807 (AV1451) molecular probe is a novel molecularly targeted imaging agent that exhibits high affinity and good selectivity for tau.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital of Fujian Medical University

Criteria

Inclusion Criteria:

• Patients or their families complain of significant memory impairment;

• Objective memory impairment (e.g., tests of article identification, recall, delayed memory);

• Be able to obtain complete diagnosis and treatment records and be able to carry out long-term follow-up;

• Signed written consent.

Exclusion Criteria:

• Psychiatric disorders: including anxiety disorder, affective disorder, severe psychosis, or drug-induced psychosis;

• Pregnancy or lactation.